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under the CC BY license (http://creaSummary Objectives: We set out to investigate the impact of common antibiotics on Panton
eValentine Leucocidin (PVL) expression by methicillin-sensitive Staphylococcus aureus (MSSA).
PVL expression by methicillin-resistant S. aureus (MRSA) is reportedly enhanced by b-lactams,
but inhibited by protein-synthesis inhibitors, a fact that has influenced management of infec-
tions associated with PVL. Although PVL is more frequently associated with MSSA than MRSA in
the UK, the effect of antibiotics on PVL expression by MSSA has not been fully addressed.
Methods: MSSA was cultured in vitro with varying concentrations of flucloxacillin, clindamycin
or linezolid and PVL expression measured by qRT-PCR and Western blotting. A murine MSSA ab-
scess model was developed to measure leucocidin expression in vivo following antibiotic treat-
ment.
Results: 9% (27/314) of MSSA isolates from patients with uncomplicated community skin/soft
tissue infections were positive for PVL genes (lukFS-PV). PVL expression by MSSA in broth
was unaffected by varying concentrations of flucloxacillin, clindamycin or linezolid. In a
murine abscess model, treatment with flucloxacillin did, however, enhance in vivo MSSA
lukF-PV transcription and this was sustained even when flucloxacillin was combined with
clindamycin, or clindamycin plus linezolid. Notwithstanding increased leucocidin transcrip-
tion, functional leucotoxin activity was not enhanced. Treatment with flucloxacillin plus
clindamycin significantly decreased leucotoxin activity, but the addition of a second protein
synthesis inhibitor, linezolid, did not confer benefit.
Conclusions: Our results suggest flucloxacillin in combination with a single protein-synthesis
inhibitor such as clindamycin would give the best treatment outcome.
ª 2015 The Authors. Published by Elsevier Ltd on behalf of the The British Infection
Associat ion. This is an open access art icle under the CC BY l icense (http://
creativecommons.org/licenses/by/4.0/).rial.ac.uk (S. Sriskandan).
.05.008
shed by Elsevier Ltd on behalf of the The British Infection Association. This is an open access article
tivecommons.org/licenses/by/4.0/).
PVL expression in MSSA 339Introduction
Staphylococcus aureus is a globally important human path-
ogen that can cause a wide spectrum of diseases attribut-
able to the range of virulence factors it is able to
express. Factors that interfere with the host innate immune
response are of critical importance to the success of the
pathogen.
PantoneValentine Leucocidin (PVL) is one of four pore
forming bi-component toxins that may be expressed by S.
aureus strains. The other three are gamma-haemolysin
(HlgABC), LukFS (also known as LukAB or LukGH) and LukDE.
The two co-transcribed components of PVL, LukS-PV and
LukF-PV, when combined can lyse human cells expressing
C5a receptors, including neutrophils.1 Strains carrying PVL
typically cause suppurative skin and soft tissue infections
and severe necrotising pneumonia.2 In north America and
spreading globally, PVL has been mainly associated with
strains of community acquired methicillin resistant S.
aureus (CA-MRSA)3,4 but UK based studies suggest a more
common association with community acquired methicillin
sensitive S. aureus (MSSA) strains.5
While there is a broad literature that addresses produc-
tion of PVL by CA-MRSA, reports investigating production by
clinical MSSA strains are limited. Previous studies have
shown that b-lactam antibiotics at sub-inhibitory concen-
trations can enhance MRSA transcription and expression of
PVL and other toxins in vitro,6e9 although the clinical rele-
vance of these studies to MSSA is complicated by the fact
that b-lactams have no antimicrobial activity against
MRSA. Antimicrobial agents targeting protein synthesis,
however, have been shown to effectively reduce transcrip-
tion and/or expression of PVL in vitro.6,10,11 Guidelines for
treating suspected PVL MRSA infections have been influ-
enced by these in vitro studies.12 Due to the potential
effect of b-lactams on toxin expression, caution is advised
with regard to use in cases of PVL-associated S. aureus
infection and the adjuvant use of one or more protein syn-
thesis inhibitors has been recommended.12 Although
b-lactams are still the treatment of choice for MSSA, the
effect of b-lactams and protein synthesis inhibitors on the
expression of toxins in clinical MSSA has not yet been fully
explored.
In this work we aimed to explore the effect of the
commonly used b-lactam flucloxacillin and two protein
synthesis inhibitors, clindamycin and linezolid, on MSSA
expression of PVL and other leucocidins. In vitro exposure
to each antibiotic at varying concentrations, including
sub-inhibitory, did not yield a significant change in either
transcription of lukF-PV or LukF-PV protein expression.
However, in vitro exposure to antibiotics does not
adequately reflect clinical exposure to antibiotics during
infection. To this end we developed a murine abscess
model to measure toxin transcription in vivo. Although
PVL has no effect on murine neutrophils and cannot be
used to model disease outcomes related to PVL, it can
be used to measure in vivo expression of toxins and other
S. aureus factors. In contrast to in vitro findings, we de-
tected a higher level of lukF-PV transcript in mice
treated with flucloxacillin compared to no antibiotic
treatment. Surprisingly, addition of clindamycin orclindamycin plus linezolid enhanced lukF-PV transcript
to an even greater level. Overall leucotoxin activity pre-
sent in the abscess following antibiotic treatment was not
affected by increased leucotoxin transcript and was in
fact significantly decreased when flucloxacillin was com-
bined with clindamycin.
Materials and methods
Bacterial strains
MSSA isolates (nZ 314), including strains HSS03 and HSS156
used throughout this study, represented isolates from
uncomplicated community SSTI collected over a one year
period (2009e2010) by a single diagnostic laboratory at
Hammersmith Hospital NHS Trust, London, UK (now ICHT).
MSSA strains were cultured on Columbia blood agar (Oxoid)
or in CCY media at 37 C shaking at 200 rpm. Minimal
inhibitory concentrations (MICs) for one MSSA PVL-positive
strain collected (HSS156) were determined, in culture using
a standard microdilution method,13 to be 0.125 mg/L for
flucloxacillin, 0.25 mg/L for clindamycin and 2 mg/L for
linezolid.
DNA extraction
Bacteria were pelleted from overnight culture and resus-
pended in 100 ml of lysis buffer (100 mM NaCl, 10 mM
TriseHCl pH8, 1 mM EDTA, 1% Triton-X-100) with 2 ml of
1 mg/ml lysostaphin and incubated for 37 C for 15 min
before boiling for 10 min. Samples were centrifuged
13,000  g for 2 min and the DNA-containing supernatant
was further purified using an equal volume of chloroform.
DNA was precipitated with isopropanol and resuspended
in ddH2O. PCR using Luk-PV primers (Table 1) was
performed to test for the presence of the lukFS-PV genes.
Separate PCR reactions were also performed using positive
control housekeeping 16s primers (Table 1) to control for
DNA quality.
In vitro exposure to antibiotics
Overnight cultures of S. aureus were diluted 1 in 10 then
cultured for 24 h in CCY media. Where antibiotics were
used, bacteria were cultured for 3 h before ¼ MIC, ½
MIC, MIC or 5x MIC of required antibiotic was added. Every
hour samples were taken, centrifuged at 2000  g for
10 min and culture supernatant 0.2 mM filtered. RNA was
extracted from bacterial cell pellets using a hot-phenol
method as previously described.14 Filtered supernatant
was concentrated 50 fold using Amicon ultra 10 kDa
MWCO spin columns (Milipore) for Western blotting.
Recombinant LukF-PV protein
LukF-PV was amplified using LukF-recombinant primers
(Table 1) and cloned into pQE-30 UA vector (Qiagen).
Recombinant protein expression was induced according
to the manufacturer’s instructions and recombinant
Table 1 Primers used in this study.
Primer name Primer sequence (50-30)
16s- forward CGGTCCAGACTCCTACGGGAGGCAGCA
16s- reverse GCGTGGACTACCAGGGTATCAATCC
Luk-PV1 ATCATTAGGTAAAATGTCTGGACATGATCCA
Luk-PV2 GCATCAACTGTATTGGATAGCAAAAGC
LukF- recombinant-F GCTCAACATATCACACCTGTAAGTG
LukF-recombinant-R TTAGCTCATAGGATTTTTTTCCTTAG
rrsA-F (qPCR) AGCTTAGTTGCCATCATTAAGTTGG
rrsA-R (qPCR) GTTGAGACTACAATCCGAACTG
LukF-PV F (qPCR) AAGCTGCTGGAAACATTTATTCTGGC
LukF-PV R (qPCR) CTGAATCTGAATTAATTGAAATGTTGTACTTAGAA
LukF F (qPCR) ATTGGAATAGTACATTAAGATGGCCTG
LukF R (qPCR) CTCCACGATTAATCGAAAAATCTC
hlgA F (qPCR) GCAGTTGGTTTAATAGCCCCTTTAG
hlgA R (qPCR) GTTATAGCTAATCGTTTGCTAGTAATGTCTTG
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tion kit (Novagen).
Western blotting
Proteins were separated by 10% Bis-Tris sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
with MES buffer (Invitrogen) and transferred to nitrocellu-
lose membrane (GE-Healthcare). Membranes were probed
using rabbit polyclonal anti-LukF-PV serum raised to the
C-terminal pentapeptide of LukF-PV (KNPMS) (Sigma-
Genosys), the sequence of which is unique to LukF-PV.
C-terminal pentapeptides have been described previously
to generate specific antibodies.15 Blots were developed
using the ECL system (GE Healthcare). LukF-PV present in
culture supernatant was quantified by densitometry
(ImageJ) in comparison to a standard curve of known
concentrations of recombinant LukF-PV that were run
alongside supernatant samples.
Quantitative real time PCR
Bacterial RNA was treated with Turbo DNAse (Ambion) and
1 mg was converted to cDNA using Transcriptor reverse
transcriptase (Roche) and random hexamer primers
(Sigma). Quantitative real time PCR was performed using
specific quantitative real time PCR primers for lukF-PV,
hlgA, lukF and the house-keeping gene rrsA (Table 1) and
SYBR green Jumpstart Taq ready mix (Sigma). Copies of
target transcript were measured against a standard curve
of a plasmid (pCR2.1, Invitrogen) containing the target
genes lukF-PV, hlgA, lukF and rrsA of known copy number,
amplified alongside bacterial cDNA. Copies of target gene
transcript were then normalised to copies of the house-
keeping gene rrsA.
In vivo exposure to antibiotics
Female Balb/c mice were infected subcutaneously in the
right flank with w2  108 colony forming units S. aureus
strain HSS156 in a 100 ml volume. Abscesses were allowedto form for 48 h. Mice were then treated intraperitone-
ally with 150 ml of either, 12.5 mg/kg flucloxacillin,
12.5 mg/kg flucloxacillin with 10 mg/kg clindamycin,
12.5 mg/kg flucloxacillin with 10 mg/kg clindamycin and
10 mg/kg linezolid, or phosphate buffered saline (PBS)
as a control. To follow standard clinical treatment of
infection, the flucloxacillin dose was repeated after 6 h
hence, over 8 h of study, mice were treated twice with
flucloxacillin. After 4 or 8 h of treatment mice were
culled and width, height and depth of abscesses were
measured using callipers to calculate abscess volume.
Pus was then extracted from abscesses and a sample
diluted and plated for bacterial enumeration which was
then calculated as total bacterial CFU per entire abscess
volume. Remaining pus was diluted in TE buffer and RNA
was extracted using a hot-phenol method previously
described14 or reserved for measuring lysis activity. RNA
was cleaned using RNeasy MinElute cleanup kit (Qiagen)
then 1 mg converted into cDNA as described above.Leucocidin activity
Total leucotoxin activity within pus from murine ab-
scesses was tested using PLB-985 cells (HL-60-like myeloid
leukaemia cell line). PLB-985 cells were cultured in
RPMIþ with 10% FCS in 5% CO2 and differentiated to a
neutrophil-like phenotype with 1.25% DMSO.16 Cells were
washed and resuspended to 1  107/ml in RMPI with
HEPES. For each pus sample, two aliquots of 245 ml
RMPI þ HEPES with 5 ml of pus were made; one was heat-
ed to 100 C for 10 min to inactivate the heat-labile
staphylococcal leucotoxins (including PVL) and control
for background leucotoxin activity. 100 ml heated or
non-heated pus aliquot was added to 100 ml PLB-985 cells
in duplicate in round bottom 96 well plates and incu-
bated for 3hrs at 37 C, 5% CO2. Samples were then
centrifuged at 700 g for 5 min and 100 ml supernatant
was transferred to flat bottom 96 well plates. LDH levels
were then measured in the supernatant using a cytotox-
icity detection kit (Roche) with an LDH standard curve
of known LDH concentrations to quantify.
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Prevalence and expression of PVL toxins among
MSSA
Between 2009 and 2010 MSSA isolates were collected from
patients with uncomplicated skin infections. Of the 314
strains tested, 9% were positive for PVL.
To determine the pattern of expression of LukF-PV
during culture, two clinical MSSA PVL positive strains
(HSS03 and HSS156) from the community uncomplicated
SSTI collection were cultured through exponential growth.
For both strains, levels of lukF-PV transcript increased dur-
ing the exponential growth phase and peaked at mid-late
exponential phase (Fig. 1). The amount of LukF-PV protein
present in the culture supernatant of strain HSS156
continued to accumulate during exponential growth and
did not diminish after overnight culture (Fig. 2).Figure 2 LukF-PV protein accumulates over exponential
growth. (a) The amount of LukF-PV protein present in the cul-
ture supernatant of strain HSS156 at each time point during
exponential growth was measured by Western blot. Recombi-
nant LukF-PV protein of known concentrations was measured
alongside in order to quantify the amount of LukF-PV by densi-
tometry. (b) The amount of LukF-PV protein (ng/ml) increases
in the culture supernatant (solid line) during exponential
growth, measured by optical density (dotted line, A600nm).
Data represent mean (standard deviation) of five individual
experiments.In vitro effect of antibiotics on PVL expression
In order to test the effect of antibiotics on the expression of
PVL in vitro, MSSA strain HSS156 was cultured to mid-
exponential phase (3 h) when expression of LukF-PV was
increasing. Flucloxacillin, clindamycin or linezolid were
then added at different concentrations; ¼MIC, ½ MIC, MIC
and 5 x MIC.
The addition of flucloxacillin, clindamycin or linezolid
resulted in either equal or reduced levels of lukF-PV tran-
script compared to the no antibiotic control at all time
points and all concentrations of antibiotic (Fig. 3).
Following two hours exposure to either flucloxacillin or clin-
damycin at all concentrations there was some reduction in
lukF-PV transcript, although only flucloxacillin 5xMIC at
4hrs resulted in a significant reduction. Linezolid had little
impact on lukF-PV transcript levels with only someFigure 1 Copies of LukF-PV transcript during exponential grow
were cultured through exponential growth (Optical density; dotted
titative real time PCR at each hour, normalized to copies per 100,0
Copies of lukF-PV transcript increased during exponential growth
were observed in both strains although strain HSS156 (a) expressed
mean (standard deviation) of five (HSS156) or two (HSS03) individreduction after 21 h of exposure suggesting a delayed ef-
fect of linezolid in vitro.
The accumulation of LukF-PV protein in the culture
supernatant was also measured (Fig. 4). A reduction inth. Two clinical MSSA PVL þ strains (a) HSS156 and (b) HSS03
line) and copies of lukF-PV transcript were measured by quan-
00 copies of the housekeeping gene transcript rrsA (Solid line).
before peaking at mid-late exponential phase. Similar results
fewer copies of transcript than strain HSS03 (b). Data represent
ual experiments.
Figure 3 The effect of antibiotic exposure on lukF-PV
transcription in vitro. Flucloxacillin (a), clindamycin (b) or
linezolid (c) was added to a culture of HSS156 in mid-
exponential phase of growth (3 h) at four concentrations; ¼
of the minimal inhibitory concentration (MIC, dark grey bars),
½ MIC (lighter grey bars), MIC (lightest grey bars) and 5x MIC
(white bars). Copies of lukF-PV transcript were measured by
quantitative real time PCR and normalized to copies per
100,000 of the house-keeping gene rrsA transcript. Data repre-
sent the mean (þstandard deviation) of 3e5 independent ex-
periments. *p  0.05 compared to no antibiotics (No Abx,
black bars) at the same time point (KruskaleWallis).
Figure 4 The effect of antibiotics on LukF-PV protein
in vitro. Flucloxacillin (a), clindamycin (b) or linezolid (c)
was added to a culture of HSS156 in mid-exponential phase
of growth (3 h) at four concentrations; ¼ of the minimal inhib-
itory concentration (MIC, dark grey bars), ½ MIC (lighter grey
bars), MIC (lightest grey bars) and 5x MIC (white bars). LukF-
PV protein concentration was measured by Western blotting
and densitometry in comparison to a standard curve of recom-
binant LukF-PV. Data represent the mean (þstandard devia-
tion) of 3e5 independent experiments. *p  0.05 compared
to no antibiotics (No Abx, black bars) at the same time point
(KruskaleWallis).
342 C.E. Turner, S. SriskandanLukF-PV protein was observed following 3 h exposure to
either flucloxacillin or clindamycin although this failed to
reach significance except at some time points (flucloxacil-
lin; MIC at 3 h, ½MIC and ¼MIC at 5 h, clindamycin;
5 x MIC at 4, 5 and 21 h). Linezolid appeared to have little
effect on LukF-PV protein levels despite the mode of activ-
ity of this antibiotic.
Examination of the culture media after 21 h of antibiotic
exposure revealed that the addition of flucloxacillin
increased the total protein content in culture media,
possibly due to b-lactam mediated bacterial cell death
releasing intracellular proteins (Supplementary Figure S1).Thus, to take into account the effect on bacterial growth,
we measured total LukF-PV protein present in the culture
supernatant without adjusting for the optical density or
number of bacteria as this measurement includes the active
expression and release of LukF-PV as well as intracellular
LukF-PV released during cell death.
In vivo effect of antibiotics on leucocidins
The concern over the effect of sub-inhibitory concentra-
tions of antibiotics on toxin production is founded in part on
PVL expression in MSSA 343the possibility that, during severe clinical disease, the
appropriate antibiotic dose may not reach the site of
infection. To test how a standard dose of antibiotic would
affect MSSA toxin expression during disease we developed a
murine abscess model of MSSA that can be used to measure
bacterial toxin transcription in vivo. Mice were infected
subcutaneously with MSSA strain HSS156 and over 48 h a
well circumscribed pus-filled abscess formed. At this time
point mice were then treated with flucloxacillin, or phos-
phate buffered saline (PBS) as a control. Four or eight hours
later mice were culled and abscesses were drained for bac-
terial enumeration and RNA extraction. There was only a
marginal, non-significant effect of flucloxacillin treatment
on total abscess bacterial load (Fig. 5a) possibly related
to the short time frame of the experiment. In contrast to
the in vitro findings however, there was an increase in
the level of lukF-PV transcript in the abscesses of mice
treated with flucloxacillin compared to control PBS treated
mice by four hours, reaching a significant 3.5 fold increase
by 8 h (Fig. 5b).
UK guidelines for treating severe PVL-associated S.
aureus, such as necrotising pneumonia, recommend the
avoidance of b-lactams and inclusion of clindamycin and
linezolid to reduce the level of toxins produced by the bac-
teria.12 To test the effect of antibiotic combination treat-
ment on PVL toxin production, the in vivo experiment was
repeated but this time groups of mice were treated with
flucloxacillin, flucloxacillin with clindamycin, flucloxacillin
with clindamycin and linezolid combined or PBS as a con-
trol. There was still little effect of antibiotic combinations
on the bacterial burden within abscesses (Fig. 6a). The
level of lukF-PV transcript was again significantly enhanced
by flucloxacillin treatment by 8 h but this increase did not
diminish when given in combination with clindamycin
(Fig. 6b). Indeed transcript levels of lukF-PV were further
enhanced when flucloxacillin was combined with clindamy-
cin and linezolid. To determine if this was specifically an ef-
fect on lukF-PV we also measured the level of transcripts
for gamma haemolysin (hlgA) (Fig. 6c) and lukF, another
bi-component leucocidin (Fig. 6d). Although flucloxacillin
alone did not affect the transcription of hlgA and lukF, inFigure 5 Flucloxacillin enhances LukF-PV expression in vivo. M
Treatment with flucloxacillin only slightly reduced total abscess ba
line, PBS) after 4 h (grey bars) and 8 h (black bars) following treat
were increased following treatment with flucloxacillin to a sign
(þstandard deviation), n Z 6 mice per group and time point. **p <combination with clindamycin or clindamycin and linezolid
the level of transcript of both toxin components were
enhanced.
The increase in transcript copy number may not, how-
ever, necessarily translate to an increase in toxin produc-
tion. Unfortunately we were unable to detect LukF-PV
protein in pus obtained from abscess by Western blot,
therefore, as a surrogate for protein expression, we
quantified total leucotoxin activity present in each abscess
by exposing the human neutrophil-like cell line PLB-985 to
pus from infected mice and measuring LDH release.
Treatment with all combinations of antibiotic reduced
overall leucotoxin activity present in pus (Fig. 7) however
only flucloxacillin with clindamycin reduced this to a signif-
icant level compared to the control PBS treated mice.Discussion
Previous in vitro studies focussing on CA-MRSA strains have
shown that sub-inhibitory concentrations of b-lactam anti-
biotics can enhance expression of PVL and other toxins,
whereas protein synthesis inhibitors reduce expression of
toxins.6e11 Guidelines for treating suspected PVL-MRSA
infection have been influenced by these studies yet there
have been limited reports regarding the effect on clinical
MSSA.
In the UK the dominant source of PVL is MSSA, particu-
larly associated with SSTI.5 We tested community SSTI-
associated MSSA strains and found 9% were positive for
PVL toxin genes. The level of PVL protein expression by
one clinical MSSA strain was w100 ng/ml, similar to that
of previously tested CA-MRSA (50e350 ng/ml).17
Following exposure to antibiotics in vitro, we did not
find a significant effect of the b-lactam flucloxacillin on
PVL expression in a clinical MSSA strain, at sub-inhibitory
concentrations or otherwise, although in some instances
transcription appeared to be marginally reduced. This is
in contrast to previous studies indicating enhanced tran-
scription of PVL following exposure of CA-MRSA to b-lactam
antibiotics.7e10 This suggests a difference in response toice were infected subcutaneously leading to abscess formation.
cterial burden (a) compared to control (phosphate buffered sa-
ment. Copies of lukF-PV transcript within the abscess however
ificant level by 8 h of treatment (b). Data represent mean
0.01 KruskaleWallis compared to control at 4 h.
Figure 6 Antibiotic treatment affects transcription of leucotoxins. Mice were treated with either flucloxacillin or flucloxacillin
in combination with clindamycin or clindamycin with linezolid. (a) All antibiotic combinations had little effect on the bacterial load
within the abscess in the short time period of 4 h (grey bars) and 8 h (black bars). Copies of lukF-PV transcript (b), hlgA transcript
(c) and lukF transcript (d) were measured within the abscess after 4 h treatment or 8 h treatment. Data represent mean (þstandard
deviation), n Z 6 mice per group and time point. *p  0.05 **p  0.01 ***p  0.001 KruskaleWallis compared to control at 4 h.
Figure 7 Residual lytic activity present in pus is reduced
by antibiotic treatment. Pus was extracted from the abscesses
of mice treated with either flucloxacillin or flucloxacillin in
combination with clindamycin or clindamycin with linezolid
for 8 h and tested for lytic activity against the cell line PLB-
985. Cell lysis was measured by LDH release (units of LDH per
ml, U/ml). Data represent mean (þstandard deviation),
n Z 6 mice per group. *p  0.05 KruskaleWallis compared to
control (PBS treated mice).
344 C.E. Turner, S. Sriskandanb-lactams between MSSA and CA-MRSA but could also be
due to different methods and time points tested. We also
demonstrated a similar effect on MSSA PVL transcription
following exposure to clindamycin and linezolid. The effect
of all three antibiotics on PVL protein expression was also
limited at all concentrations and time points, remaining
equal or marginally reduced compared to the no antibiotic
control. This was unexpected in the case of clindamycin
and linezolid, given their mode of action but may reflect
a delayed or more subtle response in liquid culture. A pre-
vious in vitro study using simulated clinical doses found at
much later time points (48 and 72 h), linezolid actually
increased PVL transcription by CA-MRSA although decreased
PVL protein expression.11
Exposure to and subsequent effects of systemic anti-
biotics in vivo are likely to be quite different to the ef-
fects of antibiotics in broth in vitro. The murine
subcutaneous abscess model allowed us to effectively
measure the level of toxin transcript produced by MSSA
during abscess formation. Surprisingly, we did identify
an increase in the level of lukF-PV transcript following
treatment of mice with flucloxacillin compared to mice
that received only PBS as a control. This is consistent
with a previous study identifying an increase in PVL tran-
scription in a murine lung infection model following
treatment with imipenem.18 Enhancement of lukF-PV
transcript was more pronounced when clindamycin was
PVL expression in MSSA 345included in the treatment and even more so when clinda-
mycin and linezolid were combined with flucloxacillin.
PVL was not the only toxin to be affected as an increase
in transcript of gamma-haemolysin component hlgA and
lukF were also observed. LukF of LukFS (not PVL) is also
known as LukG from the bi-component toxin LukGH19 or
LukB from the bi-component toxin LukAB.20 In our MSSA
strain LukF was transcribed at a much lower level compared
to LukF-PV.
The LukS component of PVL targets human C5a re-
ceptors on the surface of cells, hence the cytotoxic activity
of PVL is restricted to cells expressing this receptor.
Although PVL is cytotoxic towards human and rabbit
neutrophils it displays no activity towards murine neutro-
phils.1 Our murine abscess model is not intended for study
of the activity and downstream effects of PVL in vivo and
we did not look at disease outcomes. Instead the model
was used as an in vivo biological system to evaluate toxin
production.
We were unable to detect LukF-PV in abscess pus by
Western blot and we therefore used a surrogate test of
measuring leucotoxin activity of pus towards a human
neutrophil-cell line PLB-985. This test measured total
leucotoxin activity and was not restricted to PVL. Fluclox-
acillin in combination with clindamycin significantly
reduced the ability of abscess pus to lyse PLB-985 cells.
When linezolid was also included in treatment, this
reduction in lytic activity was lost. It has been shown
previously that linezolid and clindamycin act synergisti-
cally to reduce toxin expression.21 Our study, although
limited by a single MSSA strain, does however suggests
that, at least in the presence of flucloxacillin, this may
not be the case.
The method used to measure transcription in the current
report measured transcript copy number in relation to an S.
aureus housekeeping gene, thus this does not take bacterial
abundance into consideration. As such, the impact of tran-
scription may be heavily tempered by bacterial abundance
and viability. Although the changes were not significant,
the reductions observed in bacterial CFU or a bacteriostatic
effect when using antibiotics may have been sufficient to
influence total protein production. This would be consistent
with our observation of the paradoxical increase in toxicity
when using all three antibiotics, since this combination re-
sulted in a non-significant increase in bacterial CFU. Addi-
tionally, protein synthesis inhibitors can cause an increase
in transcription due to disrupted transcriptional regulation
but their mode of action means no consequent enhance-
ment of protein production.
Further work is required to identify if clindamycin alone
is sufficient to reduce cytotoxicity or if the detrimental
effect of linezolid in this study was due to an agonistic
effect with clindamycin. The effect of rifampicin, which is
also recommended by clinical guidelines for intracellular
bacterial clearance could also be evaluated in this model,12
and it is unclear if the observed in vivo effects on MSSA
would apply to CA-MRSA; this requires further study. Our
findings do suggest that, for skin and soft tissue infections
where MSSA-PVL is suspected that combined treatment of
flucloxacillin and clindamycin would be the most effective
but that the additional inclusion of linezolid for treatment
of MSSA may be unnecessary.Conflict of interest
The authors declare no conflict of interest.
Acknowledgements
The work was supported by the UK Clinical Research
Collaboration who fund the National Centre for Infection
Prevention and Management at Imperial College London
(MRC: G0800777), and Action Medical Research. SS acknowl-
edges the NIHR-funded Biomedical Research Centre at Im-
perial. CET is an Imperial College Junior Research Fellow.
The authors would like to thank members of the ICHT
diagnostic laboratory for providing the MSSA isolates.
Appendix A. Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.jinf.2015.05.008.
References
1. Spaan AN, Henry T, van Rooijen WJ, Perret M, Badiou C,
Aerts PC, et al. The staphylococcal toxin PantoneValentine
Leukocidin targets human C5a receptors. Cell Host Microbe
2013;13:584e94.
2. Lina G, Piemont Y, Godail-Gamot F, Bes M, Peter MO,
Gauduchon V, et al. Involvement of PantoneValentine
leukocidin-producing Staphylococcus aureus in primary skin
infections and pneumonia. Clin Infect Dis 1999;29:1128e32.
3. Tristan A, Bes M, Meugnier H, Lina G, Bozdogan B, Courvalin P,
et al. Global distribution of PantoneValentine leukocidinepos-
itive methicillin-resistant Staphylococcus aureus, 2006. Emerg
Infect Dis 2007;13:594e600.
4. Vandenesch F, Naimi T, Enright MC, Lina G, Nimmo GR,
Heffernan H, et al. Community-acquired methicillin-resistant
Staphylococcus aureus carrying PantoneValentine leukocidin
genes: worldwide emergence. Emerg Infect Dis 2003;9:
978e84.
5. Shallcross LJ, Williams K, Hopkins S, Aldridge RW, Johnson AM,
Hayward AC. PantoneValentine leukocidin associated staphy-
lococcal disease: a cross-sectional study at a London hospital.
Engl Clin Microbiol Infect 2010;16:1644e8.
6. Dumitrescu O, Badiou C, Bes M, Reverdy ME, Vandenesch F,
Etienne J, et al. Effect of antibiotics, alone and in combina-
tion, on PantoneValentine leukocidin production by a Staphy-
lococcus aureus reference strain. Clin Microbiol Infect 2008;
14:384e8.
7. Dumitrescu O, Boisset S, Badiou C, Bes M, Benito Y,
Reverdy ME, et al. Effect of antibiotics on Staphylococcus
aureus producing PantoneValentine leukocidin. Antimicrob
Agents Chemother 2007;51:1515e9.
8. Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE.
Impact of antibiotics on expression of virulence-associated
exotoxin genes in methicillin-sensitive and methicillin-
resistant Staphylococcus aureus. J Infect Dis 2007;195:
202e11.
9. Rudkin JK, Laabei M, Edwards AM, Joo HS, Otto M, Lennon KL,
et al. Oxacillin alters the toxin expression profile of
community-associated methicillin-resistant Staphylococcus
aureus. Antimicrob Agents Chemother 2014;58:1100e7.
10. Otto MP, Martin E, Badiou C, Lebrun S, Bes M, Vandenesch F,
et al. Effects of subinhibitory concentrations of antibiotics on
virulence factor expression by community-acquired
346 C.E. Turner, S. Sriskandanmethicillin-resistant Staphylococcus aureus. J Antimicrob Che-
mother 2013;68:1524e32.
11. Pichereau S, Pantrangi M, Couet W, Badiou C, Lina G,
Shukla SK, et al. Simulated antibiotic exposures in an in vitro
hollow-fiber infection model influence toxin gene expression
and production in community-associated methicillin-resistant
Staphylococcus aureus strain MW2. Antimicrob Agents Chemo-
ther 2012;56:140e7.
12. HPA. Guidance on the diagnosis and management of PVL-
associated Staphylococcus aureus infections (PVL-SA) in En-
gland. 2nd ed. 2008 https://www.gov.uk/government/
publications/pvl-staphylococcus-aureus-infections-diagnosis-
and-management.
13. Andrews JM. Determination of minimum inhibitory concentra-
tions. J Antimicrob Chemother 2001;48(Suppl. 1):5e16.
14. Turner CE, Kurupati P, Jones MD, Edwards RJ, Sriskandan S.
Emerging role of the interleukin-8 cleaving enzyme SpyCEP in
clinical Streptococcus pyogenes infection. J Infect Dis 2009;
200:555e63.
15. Edwards RJ, Wrigley A, Bai Z, Bateman M, Russell H, Murray S,
et al. C-terminal antibodies (CTAbs): a simple and broadly
applicable approach for the rapid generation of protein-
specific antibodies with predefined specificity. Proteomics
2007;7:1364e72.
16. Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A,
Murphy-Ullrich JE, et al. Cell-surface calreticulin initiatesclearance of viable or apoptotic cells through trans-
activation of LRP on the phagocyte. Cell 2005;123:321e34.
17. Hamilton SM, Bryant AE, Carroll KC, Lockary V, Ma Y,
McIndoo E, et al. In vitro production of PantoneValentine leu-
kocidin among strains of methicillin-resistant Staphylococcus
aureus causing diverse infections. Clin Infect Dis 2007;45:
1550e8.
18. Dumitrescu O, Choudhury P, Boisset S, Badiou C, Bes M,
Benito Y, et al. Beta-lactams interfering with PBP1 induce Pan-
toneValentine leukocidin expression by triggering sarA and rot
global regulators of Staphylococcus aureus. Antimicrob Agents
Chemother 2011;55:3261e71.
19. Ventura CL, Malachowa N, Hammer CH, Nardone GA,
Robinson MA, Kobayashi SD, et al. Identification of a novel
Staphylococcus aureus two-component leukotoxin using cell
surface proteomics. PLoS One 2010;5:e11634.
20. Dumont AL, Nygaard TK, Watkins RL, Smith A, Kozhaya L,
Kreiswirth BN, et al. Characterization of a new cytotoxin that
contributes to Staphylococcus aureus pathogenesis. Mol Micro-
biol 2011;79:814e25.
21. Coyle EASociety of Infectious Diseases Pharmacists. Target-
ing bacterial virulence: the role of protein synthesis inhib-
itors in severe infections. Insights from the Society of
Infectious Diseases Pharmacists. Pharmacotherapy 2003;
23:638e42.
